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Busulfan/fludarabine (BuFlu) is a widely used conditioning regimen for patients with myeloid malignancies. The
sequential FLAMSA (fludarabine + Ara-C + amsacrine chemotherapy) protocol followed by either cyclophospha-
mide and total body irradiation (FLAMSA-TBI) or cyclophosphamide and busulfan (FLAMSA-Bu) has shown
remarkable activity in high-risk acute myelogenous leukemia (AML) patients. Here we compare the outcomes of
AML patients transplanted in first complete remission (CR1) or second complete remission (CR2) after condition-
ing with BuFlu or FLAMSA. Eligible patients had their first allogeneic stem cell transplantation for AML in CR1 or
CR2 between January 2005 and June 2016. Donors were matched related or unrelated with up to 1 mismatch.
Conditioning consisted of either BuFlu or FLAMSA. Propensity score matching was applied and comparisons were
performed using weighted Cox regression. BuFlu conditioning was used in 1197 patients, whereas FLAMSA-TBI
and FLAMSA-Bu were used in 258 and 141 patients, respectively. Median follow-up of survivors was 24.72
months. In univariate analysis, relapse incidence (RI) was 30.3%, 21.9%, and 23.1% in the BuFlu, FLAMSA-TBI, and
FLAMSA-Bu groups, respectively (P < .01), and nonrelapse mortality at 2 years was 16.1%, 16.4%, and 26.7%,
respectively (P < .01). Leukemia-free survival (LFS) at 2 years was 53.6%, 61.6%, and 50.1%, respectively (P = .03).
Weighted Cox regression revealed that FLAMSA-TBI compared with BuFlu was associated with lower RI (hazard
ratio [HR], .64; 95% confidence interval [CI], .42 to .98; P = .04) and a trend for better LFS (HR, .72; 95% CI, .49 toKey Words:
FLAMSA
Reduced-intensity conditioning
Nonmyeloablative conditioning
Busulfan
Fludarabinegments on page 2231.
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T. Heinicke et al. / Biol Blood Marrow Transplant 24 (2018) 22242232 22251.06; P = .09). These results suggest that compared with BuFlu, conditioning with FLAMSA-TBI leads to reduced RI
at 2 years in AML patients transplanted in CR1 or CR2.
© 2018 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.INTRODUCTION
Relapse is the most important cause of failure in the treat-
ment of acute myelogenous leukemia (AML). The European
Leukemia Net recommends allogeneic stem cell transplanta-
tion (alloSCT) in AML patients in first complete remission
(CR1) after a careful risk-benefit assessment [1]. Here, disease
specific and transplantation specific risk factors have to be
evaluated before a recommendation for an alloSCT can be
given. Generally, alloSCT is recommended if disease relapse
risk exceeds 35% to 40% without the procedure. Reduced-
intensity conditioning (RIC) before alloSCT was developed to
facilitate the use of alloSCT in patients who are not able to tol-
erate conventional myeloablative conditioning (MAC) due to
advanced age or comorbidities [2]. This group of patients (ie,
>60 years of age and thus with higher frequency of comorbid-
ities that otherwise would preclude alloSCT due to high treat-
ment-related mortality) are those with the highest incidence
of the disease [3]. The prototype RIC regimen consists of a com-
bination of busulfan at reduced dose and fludarabine (BuFlu).
Although well tolerated with a nonrelapse mortality (NRM)
rate at 4 years of around 21%, higher relapse incidence (RI)
compared with myeloablative regimens is a concern [4]. So far,
the use of RIC regimens in fit AML patients is not well defined.
The FLAMSA (fludarabine + Ara-C + amsacrine chemotherapy)-
RIC regimen consists of 4 days of antileukemic chemotherapy,
followed after 3 days of rest by a RIC regimen [5]. All patients
receive in vivo T cell depletion to reduce the risk of acute graft-
versus-host disease (aGVHD) or chronic GVHD (cGVHD). In
addition, early tapering of immunosuppression and use of pro-
phylactic/adjuvant donor lymphocyte infusions starting on day
120 after alloSCT are part of the protocol. The aim is to trans-
plant in aplasia after maximum reduction of leukemic blasts
and to harness the graft-versus-leukemia effect. FLAMSA-RIC
was originally developed for relapsed/refractory disease,
where it showed promising efficacy with 2-year leukemia-free
survival (LFS) and overall survival (OS) rates of 40% and 42%,
respectively [5]. A more recent registry study on 267 patients
showed a GVHD-free relapse-free survival (GRFS) rate at 3
years of 17.8% and an LFS of 25.6% [6]. In addition, FLAMSA has
also been used with encouraging results in high-risk AML
patients in CR1 and in AML patients with complex karyotype
transplanted as soon as possible following FLAMSA-RIC irre-
spective of response [7,8]. More recently, the Acute Leukemia
Working Party (ALWP) of the European Society for Blood and
Marrow Transplantation (EBMT) performed a retrospective
registry study on 265 intermediate- or poor-risk AML patients
transplanted in CR1 or second complete remission (CR2) after
FLAMSA-RIC. Again, promising results were reported with a 2-
year LFS of 52.8% and OS of 56.1% [9]. Several modifications of
the originally published FLAMSA-RIC protocol have been
developed. One is the FLAMSA-Bu variant, in which the 4-Gy
total body irradiation (TBI) in the original protocol is replaced
by 8 doses of i.v. busulfan (.8 mg/kg) given over 2 days.
Other published modifications include the use of treosulfan
instead of TBI or clofarabine replacing fludarabine and amsa-
crine [10-12].
However, despite accumulating evidence on activity and
tolerability, the exact role of either of the FLAMSA conditioning
regimens before alloSCT has not been defined yet because nocomparison of FLAMSA-RIC with other commonly used condi-
tioning regimens exists. Therefore, it is unclear, for example,
whether using FLAMSA-RIC protocols in patients with AML in
CR1 or CR2 is beneficial compared with other, less intensive
protocols (eg, the RIC regimen BuFlu). To this end, we com-
pared the outcomes of AML patients transplanted in CR1 or
CR2 with either the BuFlu regimen or 1 of 2 FLAMSA-RIC var-
iants (ie, FLAMSA-TBI or FLAMSA-Bu). The hypothesis was that
the FLAMSA-RIC protocols, due to their sequential design and
higher intensity compared with BuFlu, would lead to reduced
RI, which may possibly translate into improved LFS and OS.
METHODS
Study Design
This is a retrospective registry-based analysis on behalf of the ALWP of
the EBMT. The EBMT is a nonprofit, scientific society representing >600
transplant centers, mainly in Europe, that are required to report all consecu-
tive stem cell transplantations and follow-ups once a year. Data are entered,
managed, and maintained in a central database; each EBMT center is repre-
sented in this database. Audits are routinely performed to determine the
accuracy of the data. Patients provide informed consent authorizing the use
of their personal information for research purposes. Patients were eligible for
the study if they had received first alloSCT for AML in CR1 or CR2 after 1 of
the following conditioning regimens: (1) BuFlu (ie, fludarabine 5£ 30 mg/m2,
busulfan 8£ .8 mg/kg body weight with or without antithymocite globulin);
(2) FLAMSA-TBI (ie, fludarabine 4£ 30 mg/m2, amsacrine 4£ 100 mg/m2,
cytarabine 4£ 2000 mg/m2, 400-cGy TBI, cyclophosphamide 2£ 40 mg/kg
body weight [2£ 60 mg/kg body weight in case of unrelated donors (UDs)],
antithymocite globulin 3£ 10 mg/kg body weight [3£ 20 mg/kg body weight
in case of UDs]); or (3) FLAMSA-Bu, in which TBI is replaced by busulfan
8£ .8 mg/kg body weight. Matched related donors or UDs with up to 1 mis-
match (9/10) at antigen or allele level were acceptable. For all patients, infor-
mation on cytogenetic risk at first diagnosis had to be available. Cytogenetic
abnormalities were classified according to the Medical Research Council clas-
sification system [13,14]. Transplants were done in 134 centers between Jan-
uary 2005 and June 2016. Data were taken from the EBMT registry.
Endpoints and Definitions
The primary endpoint was LFS. Secondary endpoints were OS, refined
GRFS, neutrophil engraftment, aGVHD and cGVHD, RI, and NRM. Engraftment
was defined as the first of 3 consecutive days with an absolute neutrophil
count >.5£ 109/L. Relapse was defined according to standard hematologic
criteria. NRMwas defined as death from any cause in the absence of prior dis-
ease recurrence. LFS was defined as the time to either relapse or death in
remission. OS was defined as the time to death from all causes. aGVHD was
graded according to the modified Glucksberg criteria and cGVHD according
to the revised Seattle criteria [15,16]. GRFS events have been defined as grade
III to IV aGVHD, severe cGVHD, disease relapse, or death from any cause after
alloSCT [17]. All time-to-event outcomes were calculated from the date of
alloSCT. Patients with no event were censored at last contact.
Statistical Analysis
The 3 groups were compared using the Kruskal-Wallis test for quantita-
tive variables, chi-square test, or the Fisher exact test for categorical varia-
bles.
Cumulative incidence was used to estimate the endpoints of NRM, RI,
aGVHD, and cGVHD to accommodate for competing risks. To study acute and
chronic GVHD, we considered relapse and death to be competing events.
Probabilities of OS, LFS, and GRFS were calculated using the Kaplan-Meier
method. Univariate analyses were done using the Gray test for cumulative
incidence functions and the log-rank test for OS, GRFS, and LFS.
We used propensity score (PS) weighting to control for pretreatment
imbalances on observed variables. The following factors were included in the
PS model: age at transplant, status at transplantation (CR1/CR2), donor type
(matched sibling donor/UD 10/10, UD 9/10), cytogenetics (favorable, inter-
mediate, or adverse), secondary AML, Karnofsky Performance Score at trans-
plant (<90% versus 90%), sex matching (female donor to male recipient
versus other), CMV donor or recipient, in vivo T cell depletion, and year of
transplantation. PS estimation was performed using generalized boosted
models [18]. As the research question focused on the effectiveness of
Table 1
Patient Characteristics
BuFlu FLAMSA-TBI FLAMSA-Bu Test P Value FLAMSA-TBI versus BuFlu FLAMSA-Bu versus BuFlu
(n = 1197) (n = 258) (n = 141)
Follow-up (patients alive) Median (range) 24.15 (.66-136.59) 40.26 (2.36-121.48) 17.07 (.69-99.61) <103 <103 .089
Patient age, yr Median (range) (IQR) 58.8 (20.1-76) (52.6-63.4) 47 (18.1-66.8) (40.1-55.6) 59.6 (19.6-74.4) (54-64) <103 <103 .535
Year of transplantation Median (range) 2012 (2005-2016) 2011 (2005-2016) 2013 (2007-2016) <103 <103 <103
Status at transplantation CR1 979 (81.79) 192 (74.42) 113 (80.14) .025 .007 .633
CR2 218 (18.21) 66 (25.58) 28 (19.86)
Cytogenetics Good risk 89 (7.44) 20 (7.75) 4 (2.84) .003 .298 .001
Intermediate 866 (72.35) 175 (67.83) 90 (63.83)
Adverse 242 (20.22) 63 (24.42) 47 (33.33)
Diagnosis De novo AML 1021 (85.3) 230 (89.15) 106 (75.18) .001 .106 .002
Secondary AML 176 (14.7) 28 (10.85) 35 (24.82)
Donor type MSD 569 (47.54) 100 (38.76) 39 (27.66) <103 .017 <103
UD 10/10 497 (41.52) 118 (45.74) 80 (56.74)
UD 9/10 131 (10.94) 40 (15.5) 22 (15.6)
KPS at transplantation <80 49 (4.42) 10 (4.02) 10 (7.41) .262 .776 .124
80 1059 (95.58) 239 (95.98) 125 (92.59)
Missing 89 9 6
<90 301 (27.69) 41 (16.67) 32 (23.7) .001 <103 .326
90 786 (72.31) 205 (83.33) 103 (76.3)
Missing 110 12 6
FLT3 status Negative 360 (63.05) 36 (53.73) 32 (69.57) .197 .137 .377
Positive 211 (36.95) 31 (46.27) 14 (30.43)
Missing 626 191 95
NPM1 status Negative 319 (61.23) 26 (46.43) 36 (78.26) .005 .032 .022
Positive 202 (38.77) 30 (53.57) 10 (21.74)
Missing 676 202 95
Previous auto No previous auto 1162 (97.08) 258 (100) 140 (99.29) .007 .005 .124
Previous auto 35 (2.92) 0 (0) 1 (.71)
Source of SC BM 59 (4.93) 13 (5.04) 7 (4.96) .997 .941 .985
PB 1138 (95.07) 245 (94.96) 134 (95.04)
Patient sex Male 633 (52.93) 122 (47.29) 84 (59.57) .057 .10 .134
Female 563 (47.07) 136 (52.71) 57 (40.43)
Missing 1 0 0
Donor sex Donor male 727 (60.89) 172 (66.67) 95 (67.86) .084 .083 .109
Donor female 467 (39.11) 86 (33.33) 45 (32.14)
missing 3 0 1
Sex matching No female to male 958 (80.3) 226 (87.6) 124 (87.94) .004 .006 .028
Female to male 235 (19.7) 32 (12.4) 17 (12.06)
Missing 4 0 0
Patient CMV Negative 411 (34.63) 108 (42.02) 43 (30.5) .035 .025 .328
Positive 776 (65.37) 149 (57.98) 98 (69.5)
Missing 10 1 0
Donor CMV Negative 580 (48.99) 142 (55.69) 64 (45.39) .084 .052 .419
Positive 604 (51.01) 113 (44.31) 77 (54.61)
Missing 13 3 0
Donor/recipient CMV Donor/recipient 284 (24.11) 83 (32.68) 33 (23.4) .051 .042 .292
Donor+/recipient 127 (10.78) 25 (9.84) 10 (7.09)
Donor/recipient+ 293 (24.87) 58 (22.83) 31 (21.99)
Donor+/recipient + 474 (40.24) 88 (34.65) 67 (47.52)
Missing 19 4 0
In vivo TCD No 146 (12.22) 27 (10.47) 3 (2.13) .001 .431 <103
(continued on next page)
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T. Heinicke et al. / Biol Blood Marrow Transplant 24 (2018) 22242232 2227FLAMSA-Bu or FLAMSA-TBI if it were to replace BuFlu for patients having the
same characteristics of those actually receiving BuFlu, we weighted the
FLAMSA-Bu and FLAMSA-TBI groups to match the BuFlu group by estimating
the average treatment effect among the treated (ATT), with BuFlu being the
treated group. The ATT weights equal 1 for BuFlu, and it equals the ratio of
the PS to 1 minus the PS in the 2 FLAMSA groups. We checked the balance
between the groups looking to ATT-weighted means. Then, we used ATTs to
fit weighted Kaplan-Meier and cumulative incidence. Comparison between
groups were performed on cause-specific hazards using Cox proportional
hazards model weighted on the PS and factors remaining unbalanced
between groups [19] (cytogenetics, Karnofsky Performance Score, and donor
type for the comparison between FLAMSA-Bu and BuFlu; patient age for the
comparison between FLAMSA-TBI and BuFlu). All tests were 2 sided. The type
I error rate was fixed at .05 for determination of factors associated with time
to event. Analyses were performed using R statistical software version 3.2.3
(R Foundation for Statistical Computing, Vienna, Austria). PS analysis was per-
formed using the mnps function of the twang package [20]. Estimation of
weighted outcomes at 2 years was done using the rms and npsurv packages,
and weighted Cox was done using the survey package.RESULTS
Patient Characteristics
For the BuFlu group, 1197 patients were eligible, whereas
258 and 141 patients received FLAMSA-TBI and FLAMSA-Bu,
respectively. Median follow-up for survivors was 24.7 months.
Compared with BuFlu, patients treated with FLAMSA-TBI had a
longer follow-up (24.2 versus 40.3 months; P < .001). Treat-
ment groups were compared with respect to patient character-
istics (Table 1). Some differences were observed. For example,
compared with BuFlu, patients were younger and fewer
patients were in CR1 in the FLAMSA-TBI group (47 years versus
58.8 years, respectively, P < .001; 74.4% versus 81.8%, respec-
tively, P = .007). More patients in the FLAMSA-Bu group com-
pared with the BuFlu group had adverse cytogenetics (33.3%
versus 20.2%; P = .001) or suffered from secondary AML (24.8%
versus 14.7%; P = .002).Engraftment and GVHD
Neutrophil engraftment was reached with BuFlu in 99.75%
of patients compared with 97.7% in the FLAMSA-TBI group (P
< .001) and 97.1% in the FLAMSA-Bu group (P < .001), respec-
tively. Cumulative incidence of aGVHD grade II to IV and grade
III to IV by day 100 after alloSCT were 22.9% (95% confidence
interval [CI]. 20.8% to 25%) and 9.1% (95% CI, 7.7% to 10.6%),
respectively. Compared with the BuFlu group in which 21.1%
of patients experienced aGVHD II to IV, more patients did so in
the FLAMSA-TBI group (26.9%; P < .001). At 2 years after
alloSCT, cumulative incidence of cGVHD was 34% (95% CI,
31.4% to 36.5%). The rates were 34.7% (95% CI, 31.8% to 37.7%),
33.9% (95% CI, 27.6% to 40.3%), and 28% (95% CI, 19.8% to 36.8%)
in the BuFlu, FLAMSA-TBI, and FLAMSA-Bu groups, respectively
(not significant). Extensive cGVHD at 2 years was diagnosed in
16.5% (95% CI, 14.6 to 18.6) of patients. The rates were 17.3%
(95% CI, 15% to 19.8%), 16.2% (95% CI, 11.5% to 21.5%), and
11.1% (95% CI, 6% to 18%) in the BuFlu, FLAMSA-TBI, and
FLAMSA-Bu groups, respectively (not significant) (Table 2).Relapse and NRM
RI at 2 years was 28.3% (95% CI, 25.9% to 30.7%). It was 30.3%
(95% CI, 27.5% to 33.1%) in the BuFlu group compared with
21.9% (95% CI, 16.8% to 27.6%) and 23.1% (95% CI, 15.4% to
31.8%) in the FLAMSA-TBI and FLAMSA-Bu groups, respectively
(P = .002). NRM was 17.1% (95% CI, 15.1% to 19.1%). It was
16.1% (95% CI, 13.9% to 18.5%), 16.4% (95% CI, 12% to 21.4%),
and 26.7% (95% CI, 19.1% to 35%) in the BuFlu, FLAMSA-TBI, and
FLAMSA-Bu groups, respectively (P = .007) (Table 2).
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At 2 years, LFS was 54.6% (95% CI, 52% to 57.3%). It was
53.6% (95% CI, 50.5% to 56.7%), 61.6% (95% CI, 55.3% to 68%),
and 50.1% (95% CI, 40.5% to 59.8%) in the BuFlu, FLAMSA-TBI,
and FLAMSA-Bu groups, respectively (P = .03). OS at 2 years
was 61.1% (95% CI, 58.5% to 63.8%). It was 60% (95% CI, 56.9% to
63.1%), 68.3% (95% CI, 62.3% to 74.4%), and 56.4% (95% CI, 46.8%
to 66.1%) for the BuFlu, FLAMSA-TBI, and FLAMSA-Bu groups,
respectively (not significant). GRFS at 2 years was 41.1% (95%
CI, 38.5% to 43.8%). It was 40.2% (95% CI, 37.1% to 43.3%), 46.9%
(95% CI, 40.3% to 53.5%), and 38.1% (95% CI, 28.8% to 47.4%) for
the BuFlu, FLAMSA-TBI, and FLAMSA-Bu groups, respectively
(not significant) (Table 2). There were 475 (39.7%), 95 (36.8%),
and 55 (39%) deaths observed in the BuFlu, FLAMSA-TBI, and
FLAMSA-Bu groups, respectively (Table 3). On the one hand,
infection was the leading cause of death in the FLAMSA-Bu
group, accounting for 24 cases (43.6% of deaths), whereas 77
(16.2% of deaths) and 21 (22.1% of deaths) patients died from
infection in the BuFlu and FLAMSA-TBI groups, respectively.
On the other hand, there were fewer deaths due to disease
relapse in the FLAMSA-Bu (n = 13, 23.6% of deaths) group com-
pared with the BuFlu (n = 237, 49.9% of deaths) and FLAMSA-
TBI (n = 44, 46.3% of deaths) groups, respectively.
Multivariate Analysis
Weighted probabilities for RI, NRM, LFS, OS, GRFS, aGVHD II
to IV, and cGVHD at 2 years were calculated for BuFlu,
FLAMSA-TBI, and FLAMSA-Bu groups (Table 4, Figures 1, 2).
ATT are given in Supplementary Table S1.
Compared with BuFlu conditioning, FLAMSA-TBI resulted in
reduced RI at 2 years (hazard ratio [HR], .64; 95% CI, .42 to .98;
P = .04) (Table 4, Figure 1). NRM was comparable (HR, .88; 95%
CI, .44 to 1.74; P = .72). In addition, a trend for better LFS with
the FLAMSA-TBI conditioning compared with BuFlu was
observed (HR, .72; 95% CI, .49 to 1.06; P = .09). However, this
did not translate into improved OS (HR, .81; 95% CI, .54 to 1.22;
P = .32). Conditioning with FLAMSA-Bu compared with BuFlu
had no significant impact on outcome (Table 4, Figure 2). RI
(HR, .98; 95% CI,63 to 1.53; P = .93), NRM (HR, 1.45; 95% CI, .88
to 2.41; P = .14), LFS (HR, 1.15; 95% CI, .82 to 1.61; P = .39), and
OS (HR, 1.226; 95% CI, .85 to 1.77; P = .27) were all comparable.
DISCUSSION
In the present study, we retrospectively compared alloSCT
outcomes after BuFlu, FLAMSA-TBI, or FLAMSA-Bu condition-
ing in AML patients in CR1 or CR2. FLAMSA-TBI led to a reduc-
tion in RI at 2 years and to a trend for improved LFS when
compared with BuFlu. However, this did not translate intoTable 3
Causes of Death
BuFlu FLAMSA-TBI FLAMSA-Bu
(n = 475) (n = 95) (n = 55)
Cardiac Toxicity 1 (.21) 1 (1.05) 0 (0)
Hemorrhage 3 (.63) 3 (3.16) 2 (3.64)
Failure/Rejection 3 (.63) 0 (0) 0 (0)
VOD 1 (.21) 0 (0) 1 (1.82)
Infection 77 (16.21) 21 (22.11) 24 (43.64)
IP 6 (1.26) 1 (1.05) 1 (1.82)
GVHD 103 (21.68) 12 (12.63) 7 (12.73)
Original Disease 237 (49.89) 44 (46.32) 13 (23.64)
Second Malignancy 13 (2.74) 1 (1.05) 1 (1.82)
Other Transplant Related 31 (6.53) 12 (12.63) 6 (10.91)
Values are n (%).
VOD indicates veno-occlusive-disease; IP, interstitial pneumonia.
Table 4
Weighted probabilities at two years.
RI NRM LFS OS GRFS aGVHD II-IV cGVHD
BuFlu 30.3% [27.5-33.1] 16.1% [13.9-18.5] 53.6% [50.5-56.7] 60% [56.9-63.1] 40.2% [37.1-43.3] 21.6% [19.2-24] 34.7% [31.8-37.7]
FLAMSA-TBI 20% (11.1-28.1) 15.7% (5.4-24.9) 64.3% (58.1-71.1) 69.4% (65.5-73.5) 44.9% (40.7-49.5) 29.0% (16.2-39.8) 38.5% (24.6-49.8)
FLAMSA-Bu 29.3% (16.-40.5) 24.2% (14.-33.2) 46.5% (38.1-56.7) 49.4% (44.8-54.6) 33.5% (29.4-38.2) 26.0% (14.7-35.8) 29.4% (15.9-40.7)
HR (FLAMSA-TBI vs BuFlu)* 0.64 (0.42-0.98) 0.88 (0.44-1.74) 0.72 (0.49-1.06) 0.81 (0.54-1.22) 0.90 (0.65-1.25) 1.47 (0.89-2.42) 1.03 (0.67-1.60)
P (FLAMSA-TBI vs BuFlu)* 0.04 0.72 0.09 0.32 0.52 0.13 0.88
HR (FLAMSA-Bu vs BuFlu)** 0.98 (0.63-1.53) 1.45 (0.88-2.41) 1.15 (0.82-1.61) 1.23 (0.85-1,77) 1.12 (0.84-1.51) 1.13 (0.69-1.83) 0.74 (0.49-1.11)
P (FLAMSA-Bu vs BuFlu)** 0.93 0.14 0.39 0.27 0.43 0.62 0.15
* Adjusted for patient age.
** Adjusted for cytogenetics, Karnofsky performance score and donor type.
Figure 1. Comparisons of cumulative incidence (CI) of NRM (A), RI (B), and cGVHD (C), and comparisons of probability of GRFS (D), LFS (E), and OS (F) for conditioning
with BuFlu (solid line) versus FLAMSA-TBI (dashed line).
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Figure 2. Comparisons of CI of NRM (A), RI (B), and cGVHD (C), and comparisons of probability of GRFS (D), LFS (E), and OS (F) for conditioning with BuFlu (solid line)
versus FLAMSA-Bu (dashed line).
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with BuFlu showed an increased NRM (16.1% versus 26.7%; P <
.007). However, this did not remain significant in the Cox pro-
portional hazards model adjusted on the PS. Furthermore, no
significant difference could be detected in any other of the
endpoints. Infection was more often the cause of death in the
FLAMSA-Bu group (43.6% of deaths). The FLAMSA protocols,
due to their sequential design, lead to longer time in neutrope-
nia than other regimens do. This may in part explain the higher
rate of death secondary to infection in the FLAMSA patient
groups. The FLAMSA-Bu cohort comprised patients who were
older than those receiving the FLAMSA-TBI conditioning and
thus may be more vulnerable during neutropenia. Because
relapse and death from other causes are competing risks, this
may explain that a reduction in RI by FLAMSA-Bu was not
detected in our study.The RIC regimen BuFlu has a favorable tolerability, and in a
randomized study even at myeloablative dosage, NRM at
1 year was shown to be only 7.9% [21]. The question whether
more intense BuFlu is more effective has been addressed by
several studies. Chen et al. [22], in a monocentric retrospective
study, compared 2 different busulfan dosages (3.2 mg/kg body
weight versus 6.4 mg/kg body weight) in combination with
fludarabine (120 mg/kg body weight) in AML and myelodys-
plastic syndrome (MDS) patients. No significant differences in
outcomes were found. In a subset of patients with high clinical
disease risk and nonadverse (favorable or intermediate) cyto-
genetics, the regimen with 6.4 mg/kg body weight of busulfan
was associated with a trend toward improved PFS. Further-
more, the ALWP of the EBMT retrospectively compared 2 var-
iants of BuFlu (FB2 and FB4), which differ in dose intensity, in
AML patients in CR1 and CR2. NRM at 2 years was 16% and
T. Heinicke et al. / Biol Blood Marrow Transplant 24 (2018) 22242232 223121%, respectively. In AML patients in CR1 <50 years of age, an
increase in RI was detected with FB2 compared with FB4. In
those patients 50 years of age, LFS and OS were significantly
higher with FB2, although RI and NRM both were comparable
for FB2 and FB4. In the study investigating AML patients in
CR2, the more intense regimen FB4 resulted in better LFS and
OS. Interestingly, this was not explained by reduced RI for FB4
[23,24].
Retrospective studies comparing RIC with MAC in AML
patients mostly showed improved NRM with RIC but higher RI
and comparable LFS and OS [3]. Scott et al. [25] recently pub-
lished the results of a prospective randomized trial comparing
RIC (busulfan with fludarabine or busulfan with melphalan)
with MAC (busulfan/cyclophosphamide, busulfan/fludarabine,
or cyclophosphamide/TBI) in AML or MDS patients. Treatment-
related mortality was significantly lower for the RIC group,
with 4.4% in the RIC group versus 15.8% in the MAC group. In
AML patients, cumulative incidence of relapse was 15.9% (95%
CI, 9.7% to 23.5%) with MAC and 51% (95% CI, 41.2% to 60%)
with RIC. In addition, 18-month RFS and OS were significantly
better with MAC compared with RIC. In contrast to our study,
the marked difference in RI obtained with RIC versus MAC did
translate into an improved OS. The smaller difference in RI
between FLAMSA-TBI, which is of intermediate intensity, and
BuFlu in our study compared with the more marked difference
in the study comparing RIC versus MAC may explain that this
difference did not translate into an OS advantage in our study.
The previously mentioned studies suggest that in AML
patients, dose intensity of the conditioning regimen is impor-
tant. Nonmyeloablative BuFlu shows a favorable NRM, but
more intense protocols lead to lower RI. However, MAC is asso-
ciated with higher NRM in most studies, and LFS and OS are
comparable after RIC andMAC [4]. In the previously mentioned
randomized trial, TRM even in the MAC group was remarkably
low. FLAMSA is a sequential conditioning protocol of interme-
diate intensity. A recent retrospective study by the ALWP of
the EBMT in 265 intermediate- or high-risk AML patients in
either CR1 or CR2 transplanted after FLAMSA conditioning
showed 2-year LFS and OS of 52.8% and 56.1%, respectively [8].
In this study, NRM was reported to be 24%. Thus, despite its
increased intensity compared with other RIC regimens in this
high-risk population, FLAMSA appears to have a favorable tol-
erability. Nevertheless, despite its favorable toxicity and anti-
leukemic activity, FLAMSA-RIC did not result in improved LFS
or OS compared with BuFlu in our study.
Blaise et al. [26] compared BuFlu with the NMA regimen
developed in Seattle, combining fludarabine (4£ 30 mg/m2)
with TBI (2Gy) in various diseases. NRM at 1 year was 17% and
11% with BuFlu and Flu-TBI, respectively. The cumulative inci-
dence of progression or relapse at 1 year was 14% after BuFlu
compared with 37% after Flu-TBI (P < .01). However, this dif-
ference did not translate into different LFS or OS. The ALWP of
EBMT retrospectively compared BuFlu with fludarabine/mel-
phalan conditioning in AML patients [27]. RI was significantly
higher for BuFlu patients compared with fludarabine/melpha-
lan patients. However, in agreement with our study, this did
not translate into different LFS or OS. Shimoni et al. [28]
reported a comparison of 2 BuFlu regimens of different inten-
sity with 2 fludarabine/treosulfan regimens. No differences in
RI, NRM, LFS, and OS were seen in patients in CR.
More recently, a prospective study comparing RIC BuFlu
with myeloablative fludarabine/treosulfan in AML patients in
CR or MDS patients was presented [29]. Patient age was 50
years, or patients had a hematopoietic cell transplantation
comorbidity index >2. In this study, event-free survival and OSrates at 24 months were significantly better in the fludarabine/
treosulfan group (64% and 72.5%, respectively) compared with
the BuFlu group (50.4% and 56.4%, respectively). Interestingly,
RI was similar in both groups. The favorable results for the flu-
darabine/treosulfan combination may be explained by reduced
treatment-related mortality in this group compared with the
BuFlu group of 11.3% versus 28.2%, respectively.
Our study has some limitations due to its retrospective
nature, such as some degree of heterogeneity in the GVHD pro-
phylaxis, the theoretical possibility of patient selection and cen-
ter effect, having only the Karnofsky Performance Score and not
the Sorror comorbidity score (hematopoietic cell transplanta-
tion comorbidity index) available, and some missing data,
mainly onmolecular markers and minimal residual disease.
However, until results are available from a well-designed
randomized clinical trial, the results of our study are of clinical
importance, suggesting at least noninferiority of FLAMSA-TBI
compared with BuFlu in terms of RI, NRM, LFS, and OS in AML
patients transplanted in CR1 or CR2. Currently, it is unclear
whether the benefit of FLAMSA-TBI might in part depend on
comorbidity and may be more prominent in certain subsets of
patients (eg, those with minimal residual disease positivity at
time of transplantation). Therefore, prospective trials compar-
ing the FLAMSA platform with other conditioning regimens
are warranted, in which in addition to other established risk
factors, comorbidity score and minimal residual disease status
at time of transplantation have to be assessed.
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